Skip to main content

Theradiag 2020 Revenues up 8 Percent

NEW YORK — Theradiag reported on Monday an 8 percent year-over-year increase in revenues for 2020 on strong sales of its theranostics products.

For the 12-month period ended Dec. 31, 2020, Theradiag's revenues rose to €10.4 million ($12.6 million) from €9.6 million the year before. Theranostics sales climbed almost 16 percent to €5.1 million from €4.4 million, with the company's Tracker line of therapeutic drug monitoring tests selling particularly well in the US, where the products are commercialized in collaboration with HalioDx.

In vitro diagnostics revenues, meanwhile, edged up 2 percent to €5.3 million from €5.2 million with €900,000 in sales of Theradiag's SARS-CoV-2 antigen tests and related products helping to offset the impact of nonrecurring instrumentation sales recorded in 2019.

At the end of 2020, Croissy Beaubourg, France-based Theradiag had cash totaling €3.5 million.